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Myocardial circulatory insufficiency, cardiomyocyte necrosis,and apoptosis play important roles in many pathologic condi-tions of the heart. Therapeutic approaches aimed at promot-ing angiogenesis and growing new heart muscle fibers,currently undergoing intensive investigation and early clinicaltrials, therefore hold considerable promise for the future.
Genes encoding angiogenic factors and angiogenic growth factor proteins, such as
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor, are
being delivered to the target tissue to induce growth of new blood vessels. For myo-
genesis, various progenitor and stem cells are being assessed as donor cells for
implantation into the ventricular wall of injured hearts. Phase I and II clinical trials
have already been undertaken for myocardial angiogenesis. Clinical studies into
myogenesis have been recently initiated with implantation of autologous skeletal
myoblasts into myocardial scar tissue. Although the results of phase I safety stud-
ies so far are promising, the establishment of efficacy requires rigorous phase II and
III studies yet to come.
Cardiac myogenesis and angiogenesis represents a paradigm shift in our thera-
peutic approach, from substitution to regeneration of irreversibly damaged cardiac
tissues and structures. These new modalities of therapy will not be constrained by
the scarcity of donor organs, immunologic rejection, or the need for mechanical
devices requiring maintenance and replacement. Regenerative medicine and surgery
are in fact in vivo “tissue engineering.” This could be supplemented by in vitro tis-
sue engineering in which an anatomic structure such as a heart valve could be fab-
ricated with the use of a patient’s own cells, culturing and growing them in vitro on
appropriate biodegradable scaffolds. Such regenerated tissues and constructs may
not only function normally, but also should be able to grow and remodel.
Yet in the short term this new frontier contains many challenges. Optimal means
of inducing angiogenesis remain elusive, and many questions persist. For example,
the strategy of using genetically engineered cells to deliver angiogenic genes to the
target tissue has been pursued by many investigators. However, would endothelial
cell transplantation per se be useful for angiogenesis, as suggested in an accompa-
nying article by Kim and associates?1 In the presence of appropriate angiogenic fac-
tors, at present there is no evidence of a shortage of endothelial cells for
angiogenesis. These can be derived from local vascular budding (angiogenesis), as
well as from circulating pro-endothelial cells (vasculogenesis), which, as recent evi-
dence shows, could be recruited from the bone marrow.2 In vitro, endothelial cells
in culture will form tubular capillary structures only in the presence of angiogenic
growth factors. In vivo, reduction in angiogenic factor stimulus during scar remod-
eling results in the regression of vascularity with apoptosis of endothelial cells.
Thus, the observation of Kim and colleageus1 that angiogenesis was induced with
endothelial cell transplantation into a scar without increased VEGF expression is
provocative. Perhaps such a finding could be further confirmed in a future study, if
angiogenesis can indeed be induced by endothelial transplantation despite blockage
of VEGF or VEGF receptors. 
However, an increase in capillary density does not necessarily lead to better
blood perfusion, unless the capillaries mature and connect with arterial inflow.
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Many of the capillaries in the body are not open under basal
conditions. The magnitude of tissue perfusion is controlled
by the arteriolar tone, and capillaries are recruited to carry
blood flow to meet tissue demands. Thus, increase in blood
flow may not necessarily follow increased capillary density
by angiogenesis, and coronary blood flow measured ex vivo
may not represent actual blood flow in vivo.
Likewise, in the myoblast implant studies, a number of per-
plexing questions also remain. The skeletal myoblasts trans-
planted into the ventricular wall of a heart have been reported
to differentiate either into skeletal slow-twitch muscle fibers3
or transdifferentiate into cardiomyocytes.4 In one study, it was
reported that these myoblasts may express two different phe-
notypes, with skeletal muscle phenotype in the center of a
myocardial scar and features of immature cardiomyocytes at
the ischemic border zone.5 Furthermore, such myoblasts
implanted into myocardial scar have been reported to improve
systolic fiber shortening, even though no syncytial integration
of these cells with native myocardial fibers could be recog-
nized because they were surrounded by the fibrous scar tissue.6
This is curious inasmuch as an anatomic supracellular integra-
tion seems a necessary prerequisite for synchronized contrac-
tions of these new muscle cells during ventricular systole.
Clarifying such dilemmas should help us in accepting some of
the findings being reported from functional studies. 
Recently, cells other than the myoblasts, such as the adult
stem cells in the bone marrow, are being studied as donor
cells for cellular cardiomyoplasty, as they are more versatile
stem cells capable of differentiating into many phenotypes,
including cardiomyocytes, endothelial cells, and myofibrob-
lasts.7 Attempts are also being made to transfect myoblasts
and stem cells with angiogenic genes during culture before
their implantation into the myocardium, in an effort to
Editorials Chiu
achieve both cardiac angiogenesis and myogenesis simulta-
neously. There is, however, some evidence that these cells
may spontaneously express angiogenic factors in vivo and
induce angiogenesis while they differentiate, so that
whether in fact preimplant genetic engineering is required
remain to be further examined.
Central to future advancement in this new frontier is to
learn how signals are presented physically and temporally to
cells and how cells integrate multiple signals to generate a
response. With such understanding, we will learn how to
manipulate the microenvironment, both in vitro and in vivo,
so that we can better design tissues and constructs to meet
our therapeutic needs.
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